7 Oct 2026Centennial Asset ManagementCDAHeldCentennial Asset Management continues to hold Codan (ASX: CDA) because it views the electronics designer and manufacturer as a steady compounder with established technical capabilities and a long history of innovation. Founded in 1959 and selling into more than 150 countries, Codan's core exposures are metal detection and communications. Centennial notes FY26 revenue rose 30% and net profit 69%, the dividend was increased and the balance sheet moved to net cash, extending a record of 16% revenue and 18% earnings compound annual growth since 2020. The manager is particularly confident in Codan's position in unmanned communications, expecting new product applications to lift defence demand, a view reinforced by the 29 September guidance upgrade that raised the FY27 Communications growth target to 30–40%.
7 Oct 2026Centennial Asset ManagementPMEHeldCentennial Asset Management continues to hold Pro Medicus (ASX: PME) because it views the medical imaging software provider as a steady compounder. Centennial notes its Visage 7 product delivers faster image viewing, helping it win numerous high-profile US hospital contracts. Revenue and earnings have compounded at 23% and 27% a year since 2022 without any capital raising, and the company has no debt and about $216m of cash. With an estimated US market share of only 10%, the manager sees significant room for further penetration and organic growth over the next three to five years. Retention of all six contracts up for renewal in FY26 despite competitive pressure signals strong customer satisfaction, while $1.3bn of signed forward contracted revenue, up 41.3% and almost five times FY26 revenue, provides strong visibility.
Centennial Asset Management is a Sydney-based boutique fund manager led by Matthew Kidman, a well-known Australian investor and media commentator who previously worked alongside Geoff Wilson at Wilson Asset Management before founding his own firm. Centennial specializes in Australian equities, applying an active, value-with-catalyst style approach to identify mispriced companies, with a particular focus on small and mid-cap opportunities. Kidman has built a public profile through investment podcasts, columns and television appearances (including the Success and More Interesting Stuff series and Ausbiz commentary), interviewing prominent Australian investors and sharing market insights. Centennial serves wholesale and retail investors seeking active Australian equity management informed by decades of local market experience.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.
7 Oct 2026Centennial Asset ManagementCDAHeldCentennial Asset Management continues to hold Codan (ASX: CDA) because it views the electronics designer and manufacturer as a steady compounder with established technical capabilities and a long history of innovation. Founded in 1959 and selling into more than 150 countries, Codan's core exposures are metal detection and communications. Centennial notes FY26 revenue rose 30% and net profit 69%, the dividend was increased and the balance sheet moved to net cash, extending a record of 16% revenue and 18% earnings compound annual growth since 2020. The manager is particularly confident in Codan's position in unmanned communications, expecting new product applications to lift defence demand, a view reinforced by the 29 September guidance upgrade that raised the FY27 Communications growth target to 30–40%.
7 Oct 2026Centennial Asset ManagementPMEHeldCentennial Asset Management continues to hold Pro Medicus (ASX: PME) because it views the medical imaging software provider as a steady compounder. Centennial notes its Visage 7 product delivers faster image viewing, helping it win numerous high-profile US hospital contracts. Revenue and earnings have compounded at 23% and 27% a year since 2022 without any capital raising, and the company has no debt and about $216m of cash. With an estimated US market share of only 10%, the manager sees significant room for further penetration and organic growth over the next three to five years. Retention of all six contracts up for renewal in FY26 despite competitive pressure signals strong customer satisfaction, while $1.3bn of signed forward contracted revenue, up 41.3% and almost five times FY26 revenue, provides strong visibility.
Thesis Tracker